EBITDA: Income before interest, taxes, depreciation and amortization.
Valeant Pharmaceuticals International Inc. (T.BHC) had EBITDA of 4.35B for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
219.44M |
|
-- |
|
-- |
|
-- |
|
2.53B |
|
-- |
|
512.96M |
|
512.96M |
|
167.72M |
|
167.72M |
|
167.72M |
|
167.72M |
|
2.53B |
|
|
EBITDA |
4.35B |
370.90M |
|
375.00M |
|
0.59 |
|
0.58 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
36.85B |
|
-- |
|
-- |
|
-- |
|
36.32B |
|
526.93M |
|
-21.72B |
|
526.93M |
|
370.53M |
|
| Cash Flow Statement Financials | |
1.96B |
|
-831.63M |
|
-1.04B |
|
1.68B |
|
1.85B |
|
173.31M |
|
301.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.47 |
|
-- |
|
-- |
|
0.98 |
|
55.31 |
|
70.65% |
|
17.66% |
|
17.66% |
|
30.34% |
|
3.57% |
|
1.53% |
|
1.40B |
|
-- |
|
-- |
|
-- |
|
0.39 |
|
1.85 |
|
4.37 |
|
83.59 |
|
31.83% |
|
-0.77% |
|
0.46% |
|
0.57% |
|
1.42 |
|
3.74 |
|
5.22 |
|